Encorafenib, Binimetinib and Cetuximab in Subjects With Previously Untreated BRAF-mutant ColoRectal Cancer
Фаза 2
Завершено
NCT03693170
| Заболевание | BRAF V600E-mutant Metastatic Colorectal Cancer |
|---|
| Фаза | Фаза 2 |
|---|
| Спонсор | Pierre Fabre Medicament |
|---|
| Статус | Завершено |
|---|
| Участники | 95 участн. |
|---|
| Вмешательство | encorafenib, Binimetinib, Cetuximab |
|---|
| Дата начала | 17.01.2019 |
|---|
| Дата завершения | 29.06.2020 |
|---|
| Публикация результатов | 30.08.2022 |
|---|
Кратко
The purpose of this study is to evaluate the efficacy and safety of the combination of study drugs encorafenib, binimetinib and cetuximab in patients who have BRAF V600 mutant metastatic colorectal cancer and have not received any prior treatment for their metastatic disease.
Confirmed Overall Response Rate (cORR) Based on Local Tumor Assessments
From initiation of treatment to disease progression up to a maximum of 17.6 months. · percentage of confirmed responses
| 1 Arm | 47.8 percentage of confirmed responses |
|---|
Открыть в BENITIONS
Открыть на ClinicalTrials.gov
Все исследования
Страница обобщает открытые данные ClinicalTrials.gov. Это не медицинская и не инвестиционная рекомендация. Обратитесь к врачу.